Marco P. Boks, M.D., Ph.D., Rudolf Magnus Institute of Neuroscience, 2009 NARSAD Young Investigator Grantee: "Methylation as an Epigenetic Cause of Schizophrenia"
My idea is not entirely new and not entirely...
Did you know that schizophrenia affects more than 1 percent of the world's population? See NARSAD Grants at work on the latest schizophrenia research
Schizophrenia is a severe, chronic, and generally disabling brain and behavior disorder. It is most accurately described as a psychosis - a type of illness that causes severe mental disturbances that disrupt normal thoughts, speech, and behavior. Schizophrenia is believed to be caused by a combination of genetic and environmental factors.
Positive symptoms may include delusions, thought disorders, and hallucinations. People with schizophrenia may hear voices other people don't hear, or believe other people are reading their minds, controlling their thoughts, or plotting to harm them. Negative symptoms may include avolition (a lack of desire or motivation to accomplish goals), lack of desire to form social relationships, and blunted affect and emotion. Cognitive symptoms involve problems with attention and memory, especially in planning and organization to achieve a goal. Cognitive deficits are the most disabling for patients trying to lead a normal life.
Visit the Schizophrenia Research Forum, fully sponsored by the Brain & Behavior Research Foundation—a virtual community of scientists collaborating in their quest for causes, improved treatments, and better understanding of schizophrenia.
Marco P. Boks, M.D., Ph.D., Rudolf Magnus Institute of Neuroscience, 2009 NARSAD Young Investigator Grantee: "Methylation as an Epigenetic Cause of Schizophrenia"
My idea is not entirely new and not entirely...
Brain & Behavior Research Foundation Scientific Council Member Richard Keefe, Ph.D., Director of the Schizophrenia Research Group at the Duke Institute for Brain Sciences, is one of the leaders of a multi-center...
‘Second’ generation antipsychotic medications are known as atypical antipsychotic drugs (AAPD). Among them are clozapine and olanzapine (Clozaril® and Zyprexa®). Although AAPDs have proven effective with positive symptoms...
A Leader at NAMI Discusses Her Unwavering 25-Year Support of the Brain & Behavior Research Foundation
Like many donors to the Brain & Behavior Research Foundation, Janet and Myron Susin of Long Island, New...
One of the largest studies to investigate birth complications and later mental health has found that premature birth (less than 32 weeks gestation) constitutes a single, independent risk factor for a range of severe brain...
|
To date the Brain & Behavior Research Foundation has provided 2,153 grants worth $140,731,742 to researchers focused on schizophrenia and related mental illnesses. |
DONATE NOW |
Copyright © 2013 the brain & behavior research foundation





